Key Points
- Insider purchase: CFO Mark Rosenblum acquired 20,000 shares at $0.80 each on November 20 for $16,000, increasing his direct ownership to 20,177 shares per the SEC filing.
- Market reaction and company context: Shares jumped 12.3% to $0.84 on heavy trading (377,315 shares); the company shows a tiny reported market cap (~$429k), a wide 1‑year range ($0.71–$108), recently reported EPS of ($1.81) which beat the consensus (‑$33.60), and carries a "sell" rating from Wall Street Zen.
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX - Get Free Report) CFO Mark Rosenblum acquired 20,000 shares of the company's stock in a transaction on Thursday, November 20th. The shares were purchased at an average cost of $0.80 per share, with a total value of $16,000.00. Following the completion of the acquisition, the chief financial officer directly owned 20,177 shares in the company, valued at approximately $16,141.60. The trade was a 11,299.44% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Salarius Pharmaceuticals Trading Up 12.3%
Shares of NASDAQ:SLRX traded up $0.09 during trading on Friday, hitting $0.84. 377,315 shares of the company's stock were exchanged, compared to its average volume of 610,930. The firm has a market cap of $429,420.00, a P/E ratio of -0.02 and a beta of 0.40. The firm has a 50-day moving average price of $3.52 and a two-hundred day moving average price of $7.94. Salarius Pharmaceuticals, Inc. has a 1-year low of $0.71 and a 1-year high of $108.00.
Salarius Pharmaceuticals (NASDAQ:SLRX - Get Free Report) last announced its quarterly earnings data on Friday, November 14th. The company reported ($1.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($33.60) by $31.79.
Analysts Set New Price Targets
Separately, Wall Street Zen upgraded Salarius Pharmaceuticals to a "sell" rating in a research report on Friday, August 22nd.
Get Our Latest Research Report on Salarius Pharmaceuticals
Salarius Pharmaceuticals Company Profile
(
Get Free Report)
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
